{"id":12912,"date":"2024-03-01T20:02:30","date_gmt":"2024-03-01T12:02:30","guid":{"rendered":"https:\/\/vaxlab.dukekunshan.edu.cn\/?post_type=weekly-update&p=12912"},"modified":"2024-07-15T20:04:46","modified_gmt":"2024-07-15T12:04:46","slug":"issue-11-attitudes-toward-rsv-vaccine-in-china-cost-effectiveness-of-maternal-influenza-immunization-in-lmics","status":"publish","type":"weekly-update","link":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/weekly-update\/issue-11-attitudes-toward-rsv-vaccine-in-china-cost-effectiveness-of-maternal-influenza-immunization-in-lmics\/","title":{"rendered":"Issue 11 | Attitudes toward RSV vaccine in China; Cost-Effectiveness of Maternal Influenza Immunization in LMICs"},"content":{"rendered":"\n

Journal Content Recommendation<\/strong><\/p>\n\n\n\n

01<\/strong><\/p>\n\n\n\n

Perceptions about respiratory syncytial virus (RSV) and attitudes toward the RSV vaccine among the general public in China: A cross-sectional survey<\/strong><\/p>\n\n\n\n

Nearly a quarter of participants (24.3%) indicated that they had never heard of RSV. The proportion of individuals aged over 50\u2009years reporting never having heard of RSV (36.5%) and having a low knowledge level of RSV (55.3%) was significantly higher that of other younger age groups. About 60% of individuals considered a price of RSV vaccine below 200 CNY (28 USD) as acceptable. The awareness and perceived susceptibility to RSV infection were limited to the Chinese public.<\/p>\n\n\n\n

https:\/\/doi.org\/10.1080\/21645515.2024.2310916<\/a><\/p>\n\n\n\n

02<\/strong><\/p>\n\n\n\n

Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study<\/strong><\/p>\n\n\n\n

A randomized, double-blind, controlled clinical trial was conducted in healthy population aged \u2265 13 years old in China. VarV, manufactured by Sinovac (Dalian), demonstrated higher immune response and better flexibility in the immunization schedule among heathy population aged 13 years and older. Vaccination with VarV did not increase additional safety risk.<\/p>\n\n\n\n

https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.031<\/a><\/p>\n\n\n\n

03<\/strong><\/p>\n\n\n\n

Increasing vaccinations through an on-site school-based education and vaccination program: A city-wide cluster randomized controlled trial<\/strong><\/p>\n\n\n\n

The study was a 1:1 two-arm cluster randomized controlled trial, with schools randomly assigned to either the Educational Class Condition (ECC) or the Low-Intensity Information Condition (LIIC). There were significant between-group differences in favor of the ECC. When adjusting for socioeconomic and migration background, between-group differences became non-significant for MMR but remained significant for Tdap-IPV. Educational, school-based on-site vaccination appears to be a promising strategy for increasing vaccination uptake in adolescents.<\/p>\n\n\n\n

https:\/\/doi.org\/10.1111\/aphw.12528<\/a><\/p>\n\n\n\n

04<\/strong><\/p>\n\n\n\n

Potential Cost-Effectiveness of Maternal Influenza Immunisation in Low-Income Countries: An Explorative Modelling Study and Value of Information Analysis to Guide Future Clinical Research<\/strong><\/p>\n\n\n\n

A decision tree model was built to examine the potential cost-effectiveness of maternal influenza immunisation (MII) in a hypothetical low-income country compared to no vaccination, considering possible values for non-specific effects (NSE) on preterm birth in addition to vaccine-specific effects on influenza. Results suggest that even a small (5%) NSE on preterm birth may make MII a cost-effective strategy in these settings. Acquiring more information on the presence and possible size of NSE of MII could greatly reduce the uncertainty in decision-making on MII.<\/p>\n\n\n\n

https:\/\/doi.org\/10.3390\/vaccines12030232<\/a><\/p>\n\n\n\n

Global\/National Policy Updates<\/strong><\/p>\n\n\n\n

05<\/strong><\/p>\n\n\n\n

Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season<\/strong><\/p>\n\n\n\n

The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses. WHO announced the recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The recommendations issued are used by the national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season.<\/p>\n\n\n\n

https:\/\/www.who.int\/zh\/news\/item\/23-02-2024-recommendations-announced-for-influenza-vaccine-composition-for-the-2024-2025-northern-hemisphere-influenza-season<\/a><\/p>\n\n\n\n

06<\/strong><\/p>\n\n\n\n

Hengshui City will offer free HPV vaccine for 14-year-old girls<\/strong><\/p>\n\n\n\n

Hengshui City incorporated free HPV vaccination for 14-year-old girls to its 20 livelihood projects in 2024. Two doses of domestic bivalent HPV vaccine are offered to girls born between January 1, 2010 to December 31, 2010, who are either studying in Hengshui City or have household registration in Hengshui City but study elsewhere, provided they have no prior history of HPV vaccination.<\/p>\n\n\n\n

https:\/\/www.hsrb.com.cn\/detail\/170908848721155.html<\/a><\/p>\n\n\n\n

Content Editor: Tianyi Deng<\/p>\n\n\n\n

Page Editor: Jiaqi Zu\/Ziqi Liu<\/p>\n","protected":false},"excerpt":{"rendered":"

Journal Content Recommendation 01 Perceptions about respiratory syncytial virus (RSV) and attitudes toward the RSV vaccine among the general public in China: A cross-sectional survey Nearly a quarter of participants (24.3%) indicated that they had never heard of RSV. The proportion of individuals aged over 50\u2009years reporting never having heard of RSV (36.5%) and having […]<\/p>\n","protected":false},"featured_media":12335,"menu_order":0,"template":"","format":"standard","class_list":["post-12912","weekly-update","type-weekly-update","status-publish","format-standard","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/weekly-update\/12912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/weekly-update"}],"about":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/types\/weekly-update"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media\/12335"}],"wp:attachment":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media?parent=12912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}